GlassScriptPhysician profile
Jasondeep Cheema
NPI 1083189757
$4,659.32
in general payments reported to CMS, 2019-2025
26 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $1,436 · 2023: $701 · 2024: $1,333 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,014 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,013.71 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.94 | 2022-2025 | |
| Incyte Corporation | $697.22 | 2022-2025 | Opzelura |
| Amgen INC. | $683.33 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $480.13 | 2022-2025 | |
| Journey Medical Corporation | $374.39 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $217.74 | 2024-2025 | Zoryve |
| Viiv Healthcare Company | $205.18 | 2021-2025 | Apretude, Cabenuva |
| Leo Pharma INC. | $148.91 | 2022-2025 | Adbry |
| Medimetriks Pharmaceuticals, INC. | $113.94 | 2025 | Genadur, Neo-Synalar, Clindacin Etz |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Lilly USA, LLC | $92.77 | 2022-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $90.26 | 2024 | Dupixent |
| Gilead Sciences, INC. | $74.43 | 2021-2025 | |
| Janssen Biotech, INC. | $74.30 | 2022-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.21 | 2024 | Cabtreo, Jublia, Arazlo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $60.32 | 2022 | |
| Sun Pharmaceutical Industries INC. | $55.80 | 2024 | |
| Mayne Pharma Commercial LLC | $53.71 | 2023-2024 | |
| Ucb, INC. | $47.66 | 2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $44.30 | 2025 | Veregen |
| Boston Scientific Corporation | $41.54 | 2024 | Rezum Generator |
| Novartis Pharmaceuticals Corporation | $41.31 | 2025 | |
| Pfizer INC. | $34.95 | 2023-2024 | |
| Tolmar, INC. | $25.95 | 2023 | |
| Galderma Laboratories, L.P. | $16.40 | 2025 | Aklief |
| Napo Pharmaceuticals INC | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasondeep Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.